Feedback

Discovery of Polyphenolic Natural Products as SARS-CoV-2 M pro Inhibitors for COVID-19

ORCID
0000-0002-4413-8699
Affiliation
Infection Biology Unit, German Primate Center, Leibniz Institute for Primate Research Göttingen, Kellnerweg 4, 37077 Göttingen, Germany
Krüger, Nadine;
ORCID
0000-0001-6933-7590
Affiliation
Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Kronenberger, Thales;
Affiliation
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China
Xie, Hang;
ORCID
0000-0002-0148-9405
Affiliation
Infection Biology Unit, German Primate Center, Leibniz Institute for Primate Research Göttingen, Kellnerweg 4, 37077 Göttingen, Germany
Rocha, Cheila;
ORCID
0000-0001-6086-9136
Affiliation
Infection Biology Unit, German Primate Center, Leibniz Institute for Primate Research Göttingen, Kellnerweg 4, 37077 Göttingen, Germany
Pöhlmann, Stefan;
Affiliation
State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
Su, Haixia;
Affiliation
School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China
Xu, Yechun;
ORCID
0000-0001-6952-1486
Affiliation
Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Laufer, Stefan A.;
ORCID
0000-0001-5575-8896
Affiliation
Institute of Pharmacy, Pharmaceutical/Medicinal Chemistry and Tübingen Center for Academic Drug Discovery, Eberhard Karls University Tübingen, Auf der Morgenstelle 8, 72076 Tübingen, Germany
Pillaiyar, Thanigaimalai

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has forced the development of direct-acting antiviral drugs due to the coronavirus disease 2019 (COVID-19) pandemic. The main protease of SARS-CoV-2 is a crucial enzyme that breaks down polyproteins synthesized from the viral RNA, making it a validated target for the development of SARS-CoV-2 therapeutics. New chemical phenotypes are frequently discovered in natural goods. In the current study, we used a fluorogenic assay to test a variety of natural products for their ability to inhibit SARS-CoV-2 M pro . Several compounds were discovered to inhibit M pro at low micromolar concentrations. It was possible to crystallize robinetin together with SARS-CoV-2 M pro , and the X-ray structure revealed covalent interaction with the protease’s catalytic Cys145 site. Selected potent molecules also exhibited antiviral properties without cytotoxicity. Some of these powerful inhibitors might be utilized as lead compounds for future COVID-19 research.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © 2023 by the authors.

Use and reproduction: